Favorable factors for re-treatment with pegylated interferon α2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus
出版年份 2011 全文链接
标题
Favorable factors for re-treatment with pegylated interferon α2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus
作者
关键词
-
出版物
HEPATOLOGY RESEARCH
Volume 41, Issue 12, Pages 1169-1177
出版商
Wiley
发表日期
2011-09-28
DOI
10.1111/j.1872-034x.2011.00887.x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
- (2016) Eric M Yoshida et al. CANADIAN JOURNAL OF GASTROENTEROLOGY
- Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b
- (2013) Donald M. Jensen ANNALS OF INTERNAL MEDICINE
- Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring
- (2011) Alessandra Mangia et al. HEPATOLOGY
- Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan
- (2011) Tsugiko Oze et al. JOURNAL OF GASTROENTEROLOGY
- Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C
- (2011) Kazuaki Chayama et al. JOURNAL OF GASTROENTEROLOGY
- IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection: The Future of Personalized HCV Therapies
- (2010) Paul J Clark et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan
- (2010) Hiromitsu Kumada et al. HEPATOLOGY RESEARCH
- Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)
- (2010) Izumi Namiki et al. HEPATOLOGY RESEARCH
- Positive Selection of Core 70Q Variant Genotype 1b Hepatitis C Virus Strains Induced by Pegylated Interferon and Ribavirin
- (2010) Fuat Kurbanov et al. JOURNAL OF INFECTIOUS DISEASES
- Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection
- (2009) Antonio Ascione et al. GASTROENTEROLOGY
- Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C
- (2009) Maria Grazia Rumi et al. GASTROENTEROLOGY
- Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials
- (2009) Tahany Awad et al. HEPATOLOGY
- Prolonged treatment with pegylated interferon α 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan
- (2009) Sumio Watanabe et al. HEPATOLOGY RESEARCH
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
- (2009) Dongliang Ge et al. NATURE
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
- (2009) Vijayaprakash Suppiah et al. NATURE GENETICS
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
- (2009) Yasuhito Tanaka et al. NATURE GENETICS
- Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
- (2009) Christophe Hézode et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
- (2009) John G. McHutchison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
- (2009) John G. McHutchison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis, management, and treatment of hepatitis C: An update
- (2008) Marc G. Ghany et al. HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started